Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07556107 · ClinicalTrials.gov registry record · Phase 4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
A Phase 4 study, sponsored by Bassett Healthcare.
- Not yet
- Registry status
- Phase 4
- Development phase
- 852
- Enrollment target
NCT07556107 is a Phase 4 study that has not yet begun recruiting, run by Bassett Healthcare. The registered enrollment target is 852 participants.
The verdict
NCT07556107, a Phase 4 study, has not yet begun recruiting, sponsored by Bassett Healthcare.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 852 participants
- Enrollment target
Study Summary
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Interventions
- DRUG meropenem
- DRUG Piperacillin + Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07556107
The ClinicalTrials.gov registry entry for NCT07556107 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 852 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bassett Healthcare, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which meropenem is the first listed.
NCT07556107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07556107 about?
NCT07556107 is a clinical study titled "The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)". The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they...
What is the current status of trial NCT07556107?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 852 participants. The study started on 2026-06-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07556107?
The interventions under investigation include: meropenem (DRUG), Piperacillin + Tazobactam (DRUG).
Who is sponsoring clinical trial NCT07556107?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.